The global in vivo CRO market was valued at 2.3 billion in 2015. The economic efficiency offered for outsourcing rather than conducting an in-house study is expected to boost the demand over the forecast period.
Drug manufacturers’ requirement to replenish their respective pipelines as majority of the big sellers goes off patent, thereby investing a significant amount in development is one of the major reasons for the market growth. CROs diversified expertise as compared to pharmaceutical companies with respect to performing clinical trials in wide array of geographies and development of drugs in specific therapeutic areas are few factors responsible for the growing demand for the CROs in pharmaceutical segment.
Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharmaceutical companies seeking to make an entry in a new market.
Big pharmaceutical companies such as Pfizer and GlaxoSmithKline partners with local CMOs and CROs which has proven to be successful in enabling foreign companies to achieve marketing, regulatory and manufacturing goals in the emerging economies.
The preclinical studies for cancer are driven by the personalized approach which is the currently trending therapy. Preclinical studies also impact the overall efficiency and attrition rate for drugs in clinical trials and hence improvement in the tools, designs and models of preclinical studies are expected to multiply the chances of approval, thereby propelling the market growth.
In Vivo CRO market, 2015
The in vivo CRO market has been segmented on the basis of animals used to conduct the experiment in the type outlook. These have been broadly classified into rodent and non-rodent type which is further sub-segmented to understand the majorly used species. Mice and rat are the predominantly used animals for preclinical evaluation and together are expected to hold above 70.0% of the market share over the forecast period. For the purpose of sound research, most of the experiments are conducted on one rodent and one non-rodent species.
Rodent-based preclinical testing for drug discovery and disease pathology forms the largest segment of the market. Mice and rats are studied to have a chromosomal make-up that is similar to humans and thus propelling the testing in these species. Owing to increasing R&D for cancer, aging, HIV/AIDS, Alzheimer’s, obesity, immunology, drug addiction, diabetes, alcoholism, and behavioral sciences, the demand for rodent based market is expected to boost over the forecast period.
Based on diseases, the In-Vivo CRO market has been segmented into autoimmune/ inflammation conditions, pain management, oncology, CNS conditions, diabetes, obesity, and others. As of 2015, majority of the work is being done in the field of oncology, which contributes to over 25.0% of the market share.
This share is attributed to the rising cases of cancer across the globe and the increasing focus of pharmaceutical players on introducing novel drug treatments with fewer side-effects. However, over the forecast period, the pain management category is expected to witness the fastest growth at a CAGR of over 9.0%.
Research of the autoimmune conditions in the rodent species is well-established in the mature regions of the market. The presence of various CROs catering to services for autoimmune disease testing and evaluation are expected to drive the market over the forecast period. For instance, The Jackson Laboratory offers various mouse models to perform efficacy studies of therapeutic compounds for a variety of autoimmune conditions.
North America held substantial share of over 45.0% in the in vivo CRO market in 2015. This can be attributed to the presence of technologically advanced CROs present in this region. The U.S. has the highest per capita healthcare spending and availability of funding and grants from government organizations such as the National Institute of Health (NIH) fosters research activities.
For instance, approximately 47.0% of NIH-funded research involves experimentation on non-human animals and in 2012, the NIH budgeted nearly USD 30.0 billion for research and development. The trend for reducing the R&D cost level is most common in major life sciences companies.
Clinical trial sponsors are facing huge pressure owing to the increasing complexity in the research methodology to reduce time and cost. The increasing R&D activities and need to reduce the overall trial expenditure are expected to drive the need for CROs in North America
The Asia Pacific in vivo CRO market is projected to witness lucrative growth over the forecast period. The presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and huge patient base are some factors responsible for the rapid growth. This region also ranks on top in ease of doing business.
Competitive Market Share Insights
Some key players in the in vivo CRO market are Quintiles, Charles River Laboratories, Covance, Parexel, ICON Plc. The market players are actively involved in strategic collaborations such as mergers and acquisitions, and joint ventures.
For instance, Covance was acquired by LabCorp in 2015 which is expected to provide the latter with strategic opportunities in the field of drug development.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.